A Double Blind, Randomised, Placebo-controlled, 2-period, Cross-over Study in Healthy Volunteers to Investigate the Effects of a Single Dose of Inhaled AZD7624 on White Blood Cells and Inflammatory Markers in Induced Sputum and Blood After Oral Inhalation of 45,000 Endotoxin Units Lipopolysaccharide (LPS)
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2015
At a glance
- Drugs AZD 7624 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 20 May 2015 Results (n=30) presented at the 111th International Conference of the American Thoracic Society.
- 06 May 2014 Trial status changed to completed as reported by ClinicalTrials.gov.
- 15 Oct 2013 Planned initiation date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.